Eledon PharmaceuticalsELDN +0.51%21 Quick Ratio is 8.44 as of Mar. 2026, which is 21% below its 10-year median of 10.64. GuruFocus rates ELDN with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, Eledon Pharmaceuticals ranks better than 74.03% on this metric.
Eledon Pharmaceuticals has a quick ratio of 8.44. It generally indicates good short-term financial strength.
The historical rank and industry rank for Eledon Pharmaceuticals's Quick Ratio or its related term are showing as below:
ELDN'
s Quick Ratio Range Over the Past 10 Years
Min: 0.3 Med: 10.64 Max: 46.57
Current: 8.44
During the past 13 years, Eledon Pharmaceuticals's highest Quick Ratio was 46.57. The lowest was 0.30. And the median was 10.64.
ELDN's Quick Ratio is ranked better than 74.03% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs ELDN: 8.44
Eledon Pharmaceuticals (NAS:ELDN) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Eledon Pharmaceuticals Quick Ratio Related Terms
Eledon Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Eledon Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eledon Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Eledon Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Eledon Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eledon Pharmaceuticals (ELDN) has a Quick Ratio of 8.44 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Eledon Pharmaceuticals and its competitors. This is 21% below median its historical median of 10.64. Over the past decade, Eledon Pharmaceuticals' Quick Ratio has ranged from 0.30 to 46.57. According to the industry distribution chart, Eledon Pharmaceuticals ranks #368 out of 1417 companies in the Biotechnology industry, placing it in the top 26%.
Is Eledon Pharmaceuticals' Quick Ratio too high?
Eledon Pharmaceuticals' current Quick Ratio of 8.44 is 21% below median its 10-year median of 10.64. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 46.57. The Biotechnology industry median Quick Ratio is 3.60. Eledon Pharmaceuticals' value of 8.44 is 134.4% above this industry median. Based on the distribution chart, Eledon Pharmaceuticals ranks #368 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Eledon Pharmaceuticals has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Eledon Pharmaceuticals' Quick Ratio compare to ARMP and HUMA?
According to the Biotechnology industry distribution chart, Eledon Pharmaceuticals ranks #368 out of 1417 companies for Quick Ratio. This puts Eledon Pharmaceuticals in the upper half of its industry. The industry median Quick Ratio is 3.60. Eledon Pharmaceuticals' value of 8.44 is 134.4% above this benchmark. Historically, Eledon Pharmaceuticals' own Quick Ratio has ranged from 0.30 to 46.57 over the past decade. While the company's 10-year median is 10.64 vs. the industry median of 3.60, Eledon Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eledon Pharmaceuticals's current Quick Ratio of 8.44 is 134.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Eledon Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eledon Pharmaceuticals's current Quick Ratio is 8.44, which is 21% below median its own 10-year median of 10.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eledon Pharmaceuticals stock overvalued right now?
Eledon Pharmaceuticals (ELDN) has a current Quick Ratio of 8.44. The current Quick Ratio is 8.44, which is 21% below median its 10-year median of 10.64 and 134.4% above the Biotechnology industry median of 3.60. Eledon Pharmaceuticals' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Eledon Pharmaceuticals (ELDN), the current Quick Ratio is 8.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
21GF Score
Get the complete analysis for ELDN
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELDN has been successfully added to your 
